Introduction
============

Cardiovascular disease (CVD)-related mortality has increased exponentially with increasing age worldwide^[@bib1]--[@bib3])^. Atherosclerosis is the major cause of CVD, and the appropriate management of several related risk factors is an essential step toward CVD prevention. Current guidelines for the primary prevention of CVD recommend that initial risk assessments to identify adults at high risk for CVD should be based on traditional atherosclerosis risk factors^[@bib4])^. Consequently, various tools used for CVD risk assessments are widely used in the general population, including the Framingham risk score^[@bib5])^ and the QRISK2 ^[@bib6])^. However, the predictive power of CVD risk factors reportedly decreases with advancing age^[@bib7]--[@bib9])^.

Bilateral carotid echography has recently been used to evaluate the presence of subclinical atherosclerosis. The presence of carotid plaques, as measured by echography, has been shown to serve as a surrogate marker of subclinical atherosclerosis. Several reports have also shown associations of carotid plaques with coronary heart disease and carotid intima-media thickness (IMT)^[@bib10],\ [@bib11])^. Another cohort study reported that CVD event risk prediction could be improved by adding carotid plaque metrics to traditional Framingham risk factors in a multi-ethnic population aged 45--84 years without CVD^[@bib12])^. In addition, the presence of carotid plaques, but not carotid IMT, was shown to be an independent predictor of coronary heart disease in adults aged 65--85 years^[@bib13])^. These studies suggest that the presence of carotid plaques remains a useful predictor of CVD risk in adults younger than 85 years. However, no studies have reported the relationship between the carotid plaque score (CPS) and the incidence of CVD in a general population aged ≥ 85 years.

Additionally, asymmetrical dimethylarginine (ADMA), an endogenous inhibitor of nitric oxide (NO) synthase, is a novel biomarker of endothelial dysfunction, and high levels of this molecule have been associated with incident CVD and mortality in patients with coronary artery disease, renal failure, and diabetes mellitus^[@bib14]--[@bib17])^. Plasma ADMA levels increase with age in the Framingham Offspring Study^[@bib18])^, and ADMA may be involved in atherogenic processes relevant to aging, such as endothelial cell senescence^[@bib19])^. Based on these findings, we hypothesized that ADMA is a possible moderator for the association between atherosclerosis and CVD death in the very old.

Aim
===

We aimed to clarify 1) the association between the CPS and cardiovascular mortality in a general Japanese population aged ≥ 85 years without clinical CVD and 2) whether ADMA moderated the association between the CPS and cardiovascular mortality.

Methods
=======

Design, Setting, and Participants
---------------------------------

We used data from the Tokyo Oldest Old Survey on Total Health (TOOTH) study. The TOOTH study, a community-based prospective cohort study, was established in 2008 to study the physical, mental, and oral health of the oldest old individuals living in the Tokyo Metropolitan area, Japan. Details of the TOOTH study have been described elsewhere^[@bib20])^. The TOOTH study was previously registered in the University Hospital Medical Information Network Clinical Trial Registry (ID: UMIN000001842). In addition, the present study was approved by the ethics committee of the Keio University School of Medicine (approval number: 20070047). Written informed consent was obtained from all participants.

In the present study, a total of 542 Japanese participants (236 men, 306 women) aged ≥ 85 years participated in the baseline survey from March 2008 to November 2009. We excluded 120 participants who were diagnosed with CVD at baseline, 61 who had not undergone carotid echography, and 14 with missing data. We finally analyzed data for 347 participants (151 men, 196 women; mean age, 87.6 years) without CVD. We stratified participants according to CPS into no (0 points), low (1.2--4.9 points), and high (≥ 5.0 points) CPS groups.

Baseline Examination
--------------------

All participants were assessed by trained geriatricians to determine their previous medical histories, medication use, and lifestyle risk factors (including smoking and alcohol drinking). The following diagnostic criteria were used for medical conditions. Hypertension was defined as a systolic blood pressure (BP) ≥ 140 mmHg, diastolic BP ≥ 90 mmHg, or current use of medication for hypertension. Dyslipidemia was defined as a total cholesterol (TC) level ≥ 5.70 mmol/L, high-density lipoprotein cholesterol (HDL-C) level \< 1.04 mmol/L, or current use of medication for dyslipidemia. Diabetes was defined as a non-fasting glucose level ≥ 11.1 mmol/L, glycated hemoglobin (HbA1c) level ≥ 6.5%, or current use of medication for diabetes.

Height and body weight were measured by trained staff while participants wore socks and light clothing. Body mass index (BMI) was calculated by dividing the weight in kilograms by the squared height in meters. While the participants were seated, BP was measured twice using an automatic sphygmomanometer after a minimum 5-min rest interval. We used the average of the two measurements for the analysis. Pulse pressure (PP) was defined as the difference between systolic BP and diastolic BP.

Non-fasting blood samples were collected from all participants and transported to a clinical laboratory (SRL Inc., Tokyo, Japan) for analysis. We measured serum TC, triglyceride (TG), and HDL-C levels using standard enzymatic methods. Low-density lipoprotein cholesterol (LDL-C) was calculated using Friedwald\'s formula when the TG level was \< 400 mg/dL, and the serum non-HDL-C level was calculated by subtracting the HDL-C level from the TC level. The HbA1c level was determined using high-performance liquid chromatography and reported according to the guidelines of the National Glycohemoglobin Standardization Program. The serum C-reactive protein (CRP) level was measured using a latex turbidimetric immunoassay, and the serum ADMA level was determined via high-performance liquid chromatography. The intraassay and inter-assay coefficients of variation were 2.97% and 2.50%, respectively. The serum creatinine level was measured using a standard enzymatic method, and the estimated glomerular filtration rate (eGFR) was calculated using the following formula: eGFR (mL/min/1.73 m^2^) = 194\*\[serum creatinine (mg/dL)\]^−1.094^\* \[age (years)\]^−0.287^ \[\*0.739 (if female)\]^[@bib21])^.

Two-dimensional ultrasound examinations of the bilateral common carotid arteries were performed using a 10-MHz linear transducer (Hitachi EUB-525, Hitachi Medical, Tokyo, Japan). A trained physician blinded to the participants\' clinical information performed all ultrasound examinations at the clinical site. Of the total, 61 participants who were examined at home were not eligible for this procedure. Definitions of the carotid segments were adopted from the Cardiovascular Health Study^[@bib22])^. An anterolateral approach was used to obtain a longitudinal image of the common carotid artery, and we determined the presence of focal plaque and/or calcific deposits through a thorough search of the common and internal carotid arteries. Carotid plaque was defined as a clearly identified area of focally increased thickness in the intima-media layer (\> 1.2 mm), rather than using an IMT cut-off value as previously described^[@bib23])^. CPS was calculated by summing the thickness of all plaques in the bilateral common and internal carotid arteries.

Follow-Up Survey and Outcome Measurements
-----------------------------------------

All participants were prospectively followed up for 6 years (till December 2015) via annual telephone contact or mail survey. The primary outcome was CVD death, which included any ischemic heart disease (defined using ICD-10 codes I20--I25), heart failure (I50.0), diseases of arteries (I70--I79) or stroke (defined using ICD-10 codes I60--I63, I69.0--I69.3, or G45). Events were determined based on information provided by the participants\' family or by caregivers via annual telephone contact or mail survey. When a participant\'s death was reported, a geriatrician called the family or a proxy to inquire about the date, place, and cause of death. Follow-up was continued until one of the following censoring events occurred: death from any cause, loss to follow-up (e.g., moving away from the Tokyo Metropolitan area), or the end of the 6-year follow-up period.

Statistical Analysis
--------------------

Continuous variables are shown as means and standard deviations or medians and interquartile ranges, and categorical variables are shown as numbers and proportions of participants. We compared the characteristics of participants according to CPS groups using an unpaired *t*-test or the Mann--Whitney *U* test for continuous variables, and the chi-square test or Fisher\'s exact test for categorical variables.

We estimated the cumulative cardiovascular mortality in each group using Kaplan--Meier survival curves and compared differences among the three CPS groups using the log-rank test. We used a Cox proportional hazard model to estimate the hazard ratios (HRs) with corresponding 95% confidence intervals (95% CIs) after adjusting for potential confounding factors; the low CPS group was used as a reference in all respective analyses. The confounding factors were sex (categorical variable: male, female), age (continuous variable), current smoker (categorical variable: yes, no), BMI (continuous variable), systolic BP (continuous variable) or PP (continuous variable), TC (continuous variable), HDL-C (continuous variable), HbA1c (continuous variable), estimated GFR (continuous variable), CRP (continuous variable; log-transformed), and ADMA (continuous variable; log-transformed). In addition, we performed sensitivity analysis considering competing risk of death from any causes other than CVD. Multivariate Fine and Gray\'s semiparametric proportional subdistribution hazards models were used to show sub-hazard ratios (SHRs) and 95% CIs for CVD death and non-CVD death in a competing risk situation^[@bib24])^. We also performed the same analyses stratified by ADMA level (\< 0.46 µmol/L or ≥ 0.46 µmol/L; divided by median).

Finally, we examined the abilities of two models to predict 6-year CVD death using receiver operating characteristic (ROC) curve analyses. The first (basic) model included traditional risk factors such as sex, age, smoking status, BMI, systolic BP, TC, HDL-C, HbA1c, estimated GFR, CRP, and ADMA level. The second model included all factors from the basic model, as well as the CPS groups. We calculated Harrell\'s C statistics to compare the two models.

All analyses were performed using STATA SE 13 data analysis and statistical software (Stata Corp LP, College Station, TX, USA). All *P* values for the statistical tests were two-tailed, and a *P* value \< 0.05 was considered statistically significant.

Results
=======

We analyzed data of 347 participants (151 men, 196 women; mean age, 87.6 years) without a history of CVD. All participants were included in the estimations of cumulative cardiovascular mortality and HRs for 6-year CVD death. During a follow-up comprising 609,898 person-years over a 6-year period, 109 participants (31.4%) died, and 29 (8.4%) died from CVD-related causes (ischemic heart disease death, 13; heart failure death, 4; rupture of thoracic aortic aneurysm, 1; ischemic stroke death, 4; cerebral hemorrhage death, 2; subarachnoid hemorrhage death, 1; and sudden death, 4).

**[Table 1](#T1){ref-type="table"}** presents the baseline clinical characteristics of the participants according to CPS categories. The following results were notable: the mean BMI was 21.5 kg/m^2^; only 8.1% of participants were current smokers; the mean systolic BP was 143.3 mmHg, and 51.0% of participants took medication for hypertension; the mean TC was 5.3 mmol/L, and 18.2% of participants took medication for dyslipidemia; and the mean HbA1c was 5.97%, and only 8.4% of participants took medication for diabetes. Of the total, 212 participants (61.1%) had carotid plaques, and 48 (13.8%) had a high CPS. The proportion of participants with diabetes was significantly higher, and the estimated GFR was significantly lower among participants with a high CPS versus those with no CPS. In addition, the non-fasting plasma glucose and HbA1c levels were significantly higher among participants with a high CPS. However, CPS was not found to associate with the CRP or ADMA level.

###### Characteristics of participants at baseline according to the carotid plaque score

                                                                       All                 Carotid plaque score   *P* value                               
  -------------------------------------------------------------------- ------------------- ---------------------- ------------------- ------------------- -------
  Number of participants                                               347                 135                    164                 48                  
  Male sex, n (%)                                                      151 (43.5%)         49 (36.3%)             78 (47.6%)          24 (50.0%)          0.092
  Age (years), mean (SD)                                               87.6 (2.0)          87.4 (1.6)             87.8 (2.2)          87.4 (1.8)          0.278
  Body mass index (kg/m^2^), mean (SD)                                 21.5 (3.2)          21.9 (3.1)             21.2 (3.5)          21.4 (2.6)          0.063
  Current smoker, n (%)                                                28 (8.1%)           8 (5.9%)               15 (9.2%)           5 (10.4%)           0.447
  Systolic blood pressure (mmHg), mean (SD)                            143.3 (18.8)        143.2 (19.4)           143.4 (17.9)        142.9 (20.0)        0.950
  Diastolic blood pressure (mmHg), mean (SD)                           76.5 (11.7)         77.1 (12.4)            76.7 (10.8)         74.2 (12.3)         0.359
  Pulse pressure (mmHg), mean (SD)                                     66.7 (16.0)         66.1 (16.8)            66.7 (15.6)         68.7 (15.4)         0.654
  Medication for hypertension, n (%)                                   177 (51.0%)         61 (45.2%)             85 (51.8%)          31 (64.6%)          0.067
  Hypertension, n (%)                                                  268 (77.2%)         100 (74.1%)            128 (78.1%)         40 (83.3%)          0.429
  Total cholesterol (mmol/L), mean (SD)                                5.3 (0.8)           5.3 (0.9)              5.3 (0.9)           5.1 (0.6)           0.232
  HDL cholesterol (mmol/L), mean (SD)                                  1.5 (0.4)           1.6 (0.4)              1.5 (0.4)           1.5 (0.4)           0.377
  LDL cholesterol (mmol/L), mean (SD)[\*](#tf1){ref-type="table-fn"}   3.0 (0.7)           3.0 (0.7)              3.0 (0.7)           2.9 (0.6)           0.405
  Non-HDL cholesterol (mmol/L), mean (SD)                              3.7 (0.8)           3.8 (0.8)              3.7 (0.8)           3.6 (0.7)           0.584
  Medication for dyslipidemia, n (%)                                   63 (18.2%)          26 (19.3%)             23 (14.0%)          14 (29.2%)          0.052
  Dyslipidemia, n (%)                                                  157 (45.2%)         65 (48.2%)             71 (43.3%)          21 (43.8%)          0.686
  Non-fasting plasma glucose (mmol/L), mean (SD)                       6.3 (1.9)           6.1 (1.3)              6.2 (2.2)           7.0 (2.4)           0.009
  Hemoglobin A1c (%; NGSP), mean (SD)                                  5.97 (0.72)         5.88 (0.52)            5.97 (0.75)         6.23 (0.99)         0.042
  Medication for diabetes, n (%)                                       29 (8.4%)           7 (5.2%)               13 (7.9%)           9 (18.8%)           0.021
  Diabetes, n (%)                                                      55 (15.9%)          14 (10.4%)             26 (15.9%)          15 (31.3%)          0.003
  C-reactive protein (mg/dL), median (IQR)                             0.09 (0.04--0.18)   0.08 (0.04--0.15)      0.08 (0.04--0.20)   0.13 (0.05--0.23)   0.218
  Asymmetric dimethylarginine, median (IQR)                            0.45 (0.41--0.49)   0.44 (0.41--0.49)      0.45 (0.41--0.49)   0.47 (0.41--0.51)   0.441
  Estimated GFR-creatinine (mL/min/1.73 m^2^), mean (SD)               62.3 (16.7)         65.4 (15.0)            60.9 (17.3)         58.4 (18.0)         0.006

*n* = 345

Abbreviations: HDL= high density lipoprotein, LDL = low density lipoprotein, GFR = glomerular filtration rate, SD = standard deviation, IQR = interquartile range

Cumulative cardiovascular mortality according to CPS stratification is shown in **[Fig. 1](#F1){ref-type="fig"}**. The model based on CPS categories indicated significant differences among the groups, wherein participants with a high CPS had a higher likelihood of CVD mortality than those with no or low CPS (*p* = 0.003 by the log-rank test). In addition, **[Table 2](#T2){ref-type="table"}** shows the association between CPS and CVD death in the multivariate analysis. The HR for the high CPS group was significantly higher than that for the no CPS group after adjusting for potential confounders (**[Table 2](#T2){ref-type="table"}**; HR, 3.90; 95% CI, 1.47--10.39). In this analysis, neither the ADMA nor CRP level was associated with cardiovascular mortality. Age and TC level were both significantly associated with CVD death in the multivariate analysis; however, other traditional risk factors, including the systolic BP and HbA1c levels, were not associated with CVD death. These findings were showed when PP substituted for systolic BP in multivariate model. Additionally, in sensitivity analysis considering competing risk of death from any causes other than CVD, the SHR for the high CPS group was significantly higher than that for the no CPS group after adjusting for potential confounders (**[Table 3](#T3){ref-type="table"}**; SHR, 3.14; 95% CI, 1.06--9.30) in the multivariate analysis.

![Kaplan--Meier curves of cardiovascular disease mortality according to the carotid plaque score (PS; *n* = 334). Patients were divided into three groups according to carotid PS (no, 0 points; low, 1.2--4.9 points; high, ≥ 5.0 points). *P* values were calculated using log-rank tests.](jat-25-55-g001){#F1}

###### Results of a multivariable Cox proportional hazard model with regard to CVD death

                                                                             Univariate   Multivariate                                                             
  -------------------------------------------------------------------------- ------------ -------------- ------- ------ ------------- ------- ------ ------------- -------
  Male sex                                                                   0.81         0.38--1.72     0.591   0.82   0.35--1.90    0.642   0.81   0.35--1.88    0.629
  Age, per 1 years                                                           1.20         1.06--1.36     0.004   1.26   1.09--1.46    0.002   1.27   1.09--1.47    0.002
  Body mass index, per 1 kg/m^2^                                             0.90         0.80--1.02     0.086   0.88   0.76--1.02    0.084   0.87   0.76--1.01    0.072
  Current smoker, yes                                                        0.43         0.06--3.15     0.404   0.56   0.07--4.22    0.574   0.54   0.07--4.08    0.553
  Systolic blood pressure, per 10 mmHg                                       0.91         0.75--1.11     0.359   0.93   0.76--1.14    0.514                        
  Pulse pressure, per 10 mmHg                                                0.95         0.76--1.20     0.692                                0.98   0.78--1.25    0.896
  Total cholesterol, per 1 mmol/L                                            1.22         0.80--1.86     0.367   1.67   1.04--2.70    0.036   1.65   1.02--2.67    0.040
  HDL cholesterol, per 1 mmol/L                                              1.52         0.62--3.69     0.358   1.13   0.39--3.24    0.819   1.10   0.38--3.13    0.862
  Hemoglobin A1c, per 1%                                                     0.99         0.59--1.66     0.976   0.96   0.54--1.70    0.893   0.96   0.54--1.70    0.893
  C-reactive protein, per 1 mg/dL[\*](#tf2){ref-type="table-fn"}             1.09         0.79--1.51     0.591   1.31   0.92--1.86    0.134   1.32   0.93--1.87    0.122
  Asymmetric dimethylarginine, per 1 µmol/L[\*](#tf2){ref-type="table-fn"}   1.20         0.07--19.37    0.897   0.79   0.04--15.21   0.875   0.88   0.05--16.58   0.935
  Estimated GFR-creatinine, per 1 mL/min/1.73 m^2^                           1.01         0.99--1.03     0.313   1.01   0.99--1.04    0.261   1.01   0.99--1.04    0.248
  Carotid plaque score                                                                                                                                             
      No (0 points)                                                          Ref.                                Ref.                         Ref.                 
      Low (1.2--4.9 points)                                                  0.67         0.28--1.62     0.377   0.58   0.23--1.46    0.248   0.58   0.23--1.46    0.245
      High (≥5.0 points)                                                     2.90         1.20--7.01     0.018   3.90   1.47--10.39   0.006   3.84   1.45--10.20   0.007

*n* = 347,

log-transformed

Multivariate adjustment: Model 1 adjusted for sex, age, body mass index, smoking status, systolic blood pressure, total cholesterol, HDL cholesterol, hemoglobin A1c, C-reactive protein (log-transformed), asymmetric dimethylarginine (log-transformed), and estimated GFR. Model 2 adjusted for sex, age, body mass index, smoking status, pulse pressure, total cholesterol, HDL cholesterol, hemoglobin A1c, C-reactive protein (log-transformed), asymmetric dimethylarginine (log-transformed), and estimated GFR.

Abbreviations: CVD= cardiovascular disease, HDL = high density lipoprotein, GFR=glomerular filtration rate, HR = hazard ratio, CI = confidence interval

###### Results of a multivariable Cox proportional hazard model with regard to CVD death considering competing risk of death from any causes other than CVD

                                                                             Model 1   Model 2                                  
  -------------------------------------------------------------------------- --------- ------------ ------- ------ ------------ -------
  Male sex                                                                   0.82      0.34--1.99   0.657   0.82   0.34--1.97   0.656
  Age, per 1 years                                                           1.27      1.08--1.49   0.004   1.27   1.08--1.51   0.004
  Body mass index, per 1 kg/m^2^                                             0.91      0.79--1.04   0.168   0.90   0.78--1.04   0.142
  Current smoker, yes                                                        0.51      0.07--3.67   0.505   0.49   0.07--3.62   0.485
  Systolic blood pressure, per 10 mmHg                                       0.95      0.79--1.15   0.614                       
  Pulse pressure, per 10 mmHg                                                                               1.02   0.81--1.29   0.872
  Total cholesterol, per 1 mmol/L                                            1.70      0.98--2.97   0.060   1.69   0.97--2.97   0.065
  HDL cholesterol, per 1 mmol/L                                              1.03      0.37--2.85   0.959   1.00   0.36--2.75   0.997
  Hemoglobin A1c, per 1%                                                     0.93      0.54--1.60   0.792   0.93   0.54--1.62   0.801
  C-reactive protein, per 1 mg/dL[\*](#tf3){ref-type="table-fn"}             1.17      0.79--1.72   0.439   1.17   0.79--1.74   0.428
  Asymmetric dimethylarginine, per 1 µmol/L[\*](#tf3){ref-type="table-fn"}   0.89      0.09--8.63   0.921   0.97   0.10--9.26   0.980
  Estimated GFR-creatinine, per 1 mL/min/1.73 m^2^                           1.01      0.99--1.04   0.335   1.01   0.99--1.04   0.312
  Carotid plaque score                                                                                                          
      No (0 points)                                                          Ref.                           Ref.                
      Low (1.2--4.9 points)                                                  0.59      0.24--1.47   0.258   0.59   0.24--1.46   0.252
      High (≥5.0 points)                                                     3.14      1.06--9.30   0.039   3.09   1.06--9.05   0.039

*n* = 347,

log-transformed

Multivariate adjustment: Model 1 adjusted for sex, age, body mass index, smoking status, systolic blood pressure, total cholesterol, HDL cholesterol, hemoglobin A1c, C-reactive protein (log-transformed), asymmetric dimethylarginine (log-transformed), and estimated GFR. Model 2 adjusted for sex, age, body mass index, smoking status, pulse pressure, total cholesterol, HDL cholesterol, hemoglobin A1c, C-reactive protein (log-transformed), asymmetric dimethylarginine (log-transformed), and estimated GFR.

Abbreviations: CVD = cardiovascular disease, HDL = high density lipoprotein, GFR = glomerular filtration rate, SHR = sub-hazard ratio, CI = confidence interval

To examine if ADMA moderated the association between CPS and CVD mortality, we performed the multivariate analysis stratified by median ADMA level. The significant association between the CPS and CVD death was observed in participants with lower ADMA level, but not in higher ADMA level (**[Table 4](#T4){ref-type="table"}**).

###### Multivariate adjusted hazard ratios for carotid plaque score with CVD death considering competing risk of death from any causes other than CVD stratified by ADMA level

                              Lower ADMA level   Higher ADMA level                               
  --------------------------- ------------------ ------------------- ------- ------ ------------ -------
  Carotid plaque score                                                                           
      No (0 points)           Ref.                                           Ref.                
      Low (1.2--4.9 points)   0.42               0.11--1.56          0.195   0.63   0.12--3.13   0.567
      High (≥5.0 points)      5.51               1.45--20.92         0.012   1.66   0.29--9.32   0.568

*n* = 347, \*log-transformed

Multivariate adjustment: Model adjusted for sex, age, body mass index, smoking status, systolic blood pressure, total cholesterol, HDL cholesterol, hemoglobin A1c, C-reactive protein (log-transformed), and estimated GFR.

Abbreviations: CVD = cardiovascular disease, HDL = high density lipoprotein, GFR = glomerular filtration rate, SHR = sub-hazard ratio, CI = confidence interval, ADMA = asymmetric dimethylarginine

Predictive values for CVD obtained with the basic model and basic model plus CPS groups were compared in a ROC curve analysis. The results are shown in **[Fig. 2](#F2){ref-type="fig"}**. The C statistics were 0.657 (95% CI, 0.543--0.771) for the basic model and 0.758 (95% CI, 0.666--0.851) for the basic model plus CPS groups. Compared to the basic model alone, the addition of the CPS groups significantly increased the discriminative power (*p* = 0.032).

![Receiver operating characteristic curves showing the predictive values of two models for cardiovascular disease. The basic model included sex, age, body mass index, systolic blood pressure, total cholesterol, HDL cholesterol, hemoglobin A1c, smoking status, estimated GFR, C-reactive protein (log-transformed), and asymmetric dimethylarginine (log-transformed). The C statistic was 0.657 for the basic model and 0.758 for the basic model plus the carotid plaque score.](jat-25-55-g002){#F2}

Discussion
==========

In a community-living oldest old cohort (age ≥ 85 years) with no history of CVD, we first demonstrated a correlation between a high CPS and CVD death. Although previous studies have reported an association between CPS and CVD incidence or mortality in Japanese adults^[@bib25]--[@bib27])^, the mean participant ages were lower in those studies. Participants selected for our cohort also had a low risk of CVD, characterized by a lack of CVD history, low prevalence of diabetes and dyslipidemia, and relatively low BMI. Nevertheless, the prevalence of carotid plaque was 61.1%, and the 6-year mortality of CVD only increased among those with a high plaque burden. We, therefore, conclude that a lifelong atherosclerosis burden, assessed quantitatively using carotid plaque measurements, was associated with an increased risk of CVD even in a very elderly, extremely low-risk population.

In older populations, traditional CVD risk factors (e.g., systolic BP, TC, and current smoking) have a relatively low predictive value for CVD or CVD-related mortality relative to their efficacies in younger populations^[@bib7],\ [@bib28])^. Therefore, several studies have sought to identify markers that could reliably predict CVD or CVD-related mortality in older populations^[@bib7],\ [@bib28]--[@bib31])^. In the present study, we investigated whether CPS would increase the discriminatory power for CVD prediction. Notably, the C statistic was 0.758 after adding CPS to a basic prediction model based on traditional risk factors; this value was higher than that of the basic model (0.657), indicating a significant impact of adding CPS to traditional CVD risk factors. A previous study of participants aged 45--84 years reported that the presence of carotid plaques independently predicted CVD and improved risk predictions for coronary heart disease events over a period of 7.8 years when added to the Framingham risk factors^[@bib12])^, and our results were consistent with the results of that study. We assumed that classical atherosclerosis risk factors would have little effect on CVD mortality in our cohort, possibly because at a late stage of life, these factors might not represent actual lifetime exposure to the same risk factors. Therefore, we speculate that an ultrasound examination of carotid plaque, a surrogate marker of the lifelong atherosclerotic burden, might facilitate CVD death risk evaluation even in elderly subjects with a very low cardiovascular risk.

By contrast, we were unable to demonstrate an association between ADMA and cardiovascular mortality in the present study. However, we will present some possible explanations for our results. The results of accumulating epidemiological and clinical studies of the association between ADMA concentrations and cardiovascular outcomes are conflicting and might have been modulated by population characteristics. In patients with pre-existing CVD, ADMA was associated with cardiovascular mortality or non-fatal myocardial infarction even after adjusting for traditional risk factors and B-type natriuretic peptide^[@bib15])^. ADMA was associated with an increased risk of all-cause and cardiovascular deaths in patients with stage 3--4 chronic kidney disease^[@bib16])^. In contrast, the ADMA concentration was significantly associated with all-cause mortality, but not CVD incidence, in a general middle aged population^[@bib18])^ and in very elderly community-dwelling individuals^[@bib32])^. In our very old, entirely CVD-free participants, the ability of ADMA to predict all-cause and cardiovascular mortality might be limited. Our multivariate analysis failed to find an association of ADMA with all-cause mortality during the 6-year follow-up (HR, 1.54; 95% CI, 0.35--6.79). Second, ADMA induces endothelial dysfunction by inhibiting NO synthesis; accordingly, the availability of L-arginine, a NO precursor, could modify the effect of ADMA on cardiovascular outcomes. In an Italian cohort of the very old, ADMA predicted all-cause mortality among participants with L-arginine levels \< 60 µM/L, but did not predict among those with L-arginine levels \> 60 µM/L^[@bib32])^. Unfortunately, L-arginine levels were unavailable in our study; however, this notion should be tested in future.

Despite no associations between ADMA and cardiovascular mortality, ADMA moderated association between CPS and CVD death, in which CPS was significantly associated CVD death only in those with lower ADMA levels. Because of observational nature of this study, we couldn\'t address the issue precisely. However, those who had higher ADMA levels were older and had lower eGFR levels than their counter parts (data not shown), so older age and poor renal function might be confounded association between CPS and cardiovascular mortality.

The present study had several limitations. First, the carotid plaque definition differed from that used in other reports^[@bib7],\ [@bib12])^. We defined a carotid plaque as a clearly identified area of focally increased thickness (\> 1.2 mm) in the intima-media layer to distinguish plaques clearly from carotid IMT. Previous studies demonstrated that carotid IMT at plaque-free sites in common carotid arteries increased with chronological age (up to 100 years) in a Japanese cohort^[@bib23])^, suggesting that IMT thickening might be a stage in physiological vascular aging in the oldest old. Furthermore, a recent large-scale study reported that three-dimensional ultrasound-assessed carotid plaque volume was associated with a greater carotid atherosclerosis burden than had previously been reported^[@bib33])^. Very recently, 18-Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) is a useful technique for detecting inflamed atherosclerotic plaques *in vivo*^[@bib34])^. Although we applied a simple two-dimensional ultrasound technique to determine this burden in vulnerable participants, the lack of precise carotid plaque quantification might have led to an underestimation. Second, we investigated only a limited number of biomarkers. As serum homocysteine levels have been reported to improve CVD risk predictions in the oldest old^[@bib7])^, we propose that this parameter should be included in future studies. In addition, it might be appropriate to include aging-sensitive biomarkers such as leukocyte telomere length in future studies of CVD risk in the oldest old. Finally, our study might have been under-powered because of the relatively small sample size and relatively short follow-up period. In addition, we could not evaluate the impact of CPS on specific CVD death subtypes (e.g., coronary heart disease, ischemic stroke, or cerebral hemorrhage deaths) because of the small number of each type of event. We, therefore, recommend conducting a larger cohort study with a longer follow-up period to confirm our findings in the future.

Conclusion
==========

A high CPS was significantly associated with an increase in cardiovascular mortality in our cohort of oldest old individuals with an extremely low CVD risk. ADMA was not associated with CVD death, but the significant association between CPS and CVD death was observed only in lower ADMA level. Despite the modest improvement in CVD predictability achieved by adding CPS measurements to traditional risk factors, our study provides epidemiological evidence that the lifelong atherosclerosis burden correlates with CVD risk in individuals aged ≥ 85 years. Our results may have clinical relevance to the identification of patients who would be amenable to primary CVD prevention through lifestyle modification.
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